Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 20,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood sample Clear all
Terminated No phase listed Observational

Liver and Biliary Tumor Tissue Registry

NCT02917759
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cholangiocarcinoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

NCT03029780
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Opdivo, Yervoy
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Jacksonville, Florida • Iowa City, Iowa • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 18, 2026, 4:47 PM EDT
Completed No phase listed Observational

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

NCT03789162
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
40 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
44
States / cities
Phoenix, Arizona • Canoga Park, California • Chula Vista, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 18, 2026, 4:47 PM EDT
Completed No phase listed Observational

Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease

NCT03626246
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Kidney Disease, Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Secondary Hyperparathyroidism
Interventions
Kidney disease
Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 18, 2026, 4:47 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

NCT05308446
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Cetuximab, Encorafenib, Nivolumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
282
States / cities
Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 18, 2026, 4:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fertility in Healthy Premenopausal Women

NCT02772848
View directory record Official record
Conditions
Fertility
Interventions
Not listed
Lead sponsor
Fujirebio Diagnostics, Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Hialeah, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

NCT01853748
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, Paclitaxel, Trastuzumab emtansine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
85
States / cities
Birmingham, Alabama • San Francisco, California • Hartford, Connecticut + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 18, 2026, 4:47 PM EDT
Recruiting Phase 2 Interventional

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

NCT06038578
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
TRK-950, Ramucirumab, Paclitaxel
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Duarte, California • Irvine, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00268489
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, pemetrexed disodium
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
248
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Little Rock, Arkansas + 161 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Not applicable Interventional

An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas

NCT02536950
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Fixed set point, Variable set point
Device
Lead sponsor
Bruce A. Buckingham
Other
Eligibility
18 Years to 44 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 18, 2026, 4:47 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions
Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
303
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 226 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 18, 2026, 4:47 PM EDT
Recruiting Phase 3 Interventional

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Mezagitamab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
25
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

NCT00658697
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Bevacizumab, ADT, Bicalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

NCT00162110
View directory record Official record
Conditions
Mucinous Gastrointestinal Adenocarcinoma
Interventions
cetuximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Phase 4 Interventional Results available

Mechanism of Action Study for Psoriasis

NCT00932113
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate, Adalimumab (Humira)
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

NCT01109524
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Cancer of the Lung, Non-Small-Cell Lung Carcinoma
Interventions
Cetuximab, Cisplatin, Vinorelbine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Casa Grande, Arizona • Beverly Hills, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 18, 2026, 4:47 PM EDT
Terminated Not applicable Interventional Results available

Management of Uncontrolled Hypertension (HTN)

NCT02922023
View directory record Official record
Conditions
Hypertension
Interventions
Ambulatory blood pressure monitor (ABPM), Chronotherapy
Device · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

NCT04509596
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

NCT00691015
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
Biological · Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 18, 2026, 4:47 PM EDT
Terminated Not applicable Interventional Results available

PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor

NCT03401489
View directory record Official record
Conditions
Blood Pressure, Hypertension, Mhealth
Interventions
PACESETTER
Device
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
San Francisco, California • Charleston, South Carolina • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 18, 2026, 4:47 PM EDT
Completed No phase listed Observational

Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma

NCT00900250
View directory record Official record
Conditions
Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma, Ann Arbor Stage III Childhood Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Hodgkin Lymphoma, Refractory Childhood Hodgkin Lymphoma
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
1,271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 123 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Not applicable Interventional

Cut Your Pressure Too: The Los Angeles Barbershop Blood Pressure Study

NCT02321618
View directory record Official record
Conditions
Hypertension
Interventions
BP measurement & pharmacy, BP educational materials
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 79 Years · Male only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 18, 2026, 4:47 PM EDT
Completed No phase listed Observational

Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy

NCT01869218
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 18, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Biomarker Guided Therapies in Stage A/B Heart Failure

NCT02230891
View directory record Official record
Conditions
Hypertension, Diabetes, Cardiovascular Disease
Interventions
Carvedilol, Spironolactone, Usual care
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 18, 2026, 4:47 PM EDT